【摘要】 目的 探讨奥曲肽辅助治疗乙型肝炎病毒（HBV）相关肝癌患者的临床疗效。方法 依据治疗方法的不同将106例HBV相关肝癌患者分为对照组与观察组，每组53例。两组患者均接受常规支持治疗，对照组患者采取奥沙利铂+亚叶酸钙+5-氟尿嘧啶（FOLFOX）方案化疗，观察组患者在对照组的基础上接受奥曲肽辅助治疗。比较两组患者的临床疗效、功能状态、生存情况及不良反应发生率。结果 治疗后，观察组患者的疾病控制率高于对照组，功能状态降低率低于对照组，1年生存率高于对照组，差异均有统计学意义（P﹤0.05）。观察组患者白细胞减少发生率明显低于对照组，差异有统计学意义（P﹤0.01）。结论 奥曲肽辅助治疗HBV相关肝癌患者可有效提高临床疗效和1年生存率，降低白细胞减少发生率，改善患者的功能状态。更多还原

【Abstract】 Objective To explore the clinical efficacy of octreotide in adjuvant treatment of patients with hepatitis B virus(HBV)-related liver cancer. Method A total of 106 patients with HBV-related liver cancer were divided into control group(n=53) and observation group(n=53) according to different treatment methods. Both groups received routine supportive treatment, patients in the control group were treated with oxaliplatin + leucovorin + 5-fluorouracil(FOLFOX)chemotherapy, and patients in the observation group were treated with FOLFOX chemotherapy+octreotide adjuvant treatment. The clinical efficacy, performance status, survival and adverse reactions were compared between the two groups.Result After treatment, the disease control rate of patients in the observation group was higher, the performance status reduction rate was lower, and one-year survival rate was higher than those in the control group, the differences were statistically significant(P<0.05). The incidence of leukopenia in the observation group was significantly lower than that in the control group, the difference was statistically significant(P<0.01). Conclusion Octreotide adjuvant treatment can significantly improve the clinical efficacy and one-year survival rate of patients with HBV-related liver cancer, reduce the incidence of leukopenia, and improve the performance status of patients.更多还原